| Ana Maria Argumaniz, NP | |
|
1749 Pine St, Abilene, TX 79601-3043 | |
| (325) 696-0600 | |
| Not Available |
| Full Name | Ana Maria Argumaniz |
|---|---|
| Gender | Female |
| Speciality | |
| Experience | Years |
| Location | 1749 Pine St, Abilene, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013442516 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | AP133068 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ana Maria Argumaniz, NP 1749 Pine St, Abilene, TX 79601-3043 Ph: (325) 696-0600 | Ana Maria Argumaniz, NP 1749 Pine St, Abilene, TX 79601-3043 Ph: (325) 696-0600 |
News Archive
Selected by the American Society of Clinical Oncology to first outing during its Genitourinary Cancers Symposium, Translating Evidence to Multidisciplinary Care, February 8 - 10 (San Francisco, USA), Joaquin Mateo, Principal Investigator of VHIO's recently created Prostate Cancer Translational Research Group, will today reveal findings from a retrospective and international study showing for the first time that patients with inherited DNA repair mutations benefit from standard therapies in a similar way to other metastatic prostate cancer patients.
"One in 10 cases of tuberculosis in China cannot be treated by the most commonly-used drugs, driven by a lack of testing and misuse of medicine, according to a national survey that showed for the first time the size of the drug-resistant epidemic," the Associated Press reports.
Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone.
Exalenz Bioscience has finalized production of the BreathID® and is preparing to ship the first devices and kits that are used in the detection of Helicobacter pylori bacteria. Additionally, in preparation for its American launch, the company is in the process of establishing national distribution channels. The company has recently announced the appointment of Mr. Dennis Boyle as Vice-President and National Manager in the USA. In his previous position, Mr. Boyle was director of sales and marketing to medical laboratories for Siemens USA.
› Verified 4 days ago
Jewel Monique Trancoso, APRN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2600 Ivanhoe Ln Apt 204, Abilene, TX 79605 Phone: 325-513-7293 | |
Brandon M. Goetz, N.P. Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1900 Pine St, Abilene, TX 79601 Phone: 325-670-2151 Fax: 405-321-4603 | |
Lauren Brooke Terrell, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 950 N 19th St Ste 200, Abilene, TX 79601 Phone: 325-670-5320 Fax: 325-670-5324 | |
Ms. Elizabeth Webber, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 818 Lexington Ave, Abilene, TX 79605 Phone: 325-696-0212 | |
Richard Sankara Musonera, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1749 Pine St, Abilene, TX 79601 Phone: 325-696-0600 Fax: 325-676-3873 | |
Bailey Ann Estes, APRN-CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1210 N 18th St, Abilene, TX 79601 Phone: 325-207-4734 |